Markets:

Overview

News

Currencies

International

Treasuries

Innoviva, Inc. - Common Stock (NQ:INVA)

21.82 -0.49 (-2.20%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jul 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Innoviva, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

INNOVIVA INC (NASDAQ:INVA): A Strong Growth Stock Poised for a Technical Breakout ↗

June 27, 2026

Via Chartmill

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

June 18, 2026

From Nortiva Bio, Inc.

Via Business Wire

Innoviva Inc (NASDAQ:INVA): A GARP Standout with 470% EPS Growth and a P/E of Just 6.05 ↗

June 18, 2026

Via Chartmill

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

June 16, 2026

From Innoviva Specialty Therapeutics

Via Business Wire

Innoviva to Participate in Upcoming Investor Conferences

June 01, 2026

From Innoviva, Inc.

Via Business Wire

INNOVIVA INC (NASDAQ:INVA) Scores as a Value Stock with Strong Fundamentals ↗

May 25, 2026

Via Chartmill

Innoviva Inc (NASDAQ:INVA) Screened as a Top Value Stock with Strong Fundamentals ↗

April 04, 2026

Via Chartmill

INNOVIVA INC (NASDAQ:INVA) Emerges as a High-Growth Momentum Pick Using Minervini's Trend Template ↗

March 02, 2026

Via Chartmill

Innoviva Inc (NASDAQ:INVA) Presents a Compelling Value Investment Case ↗

February 10, 2026

Via Chartmill

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More ↗

May 29, 2026

Innoviva develops respiratory pharmaceuticals through strategic partnerships and royalty agreements in the global healthcare market.

Via The Motley Fool

Topics Regulatory Compliance

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

May 06, 2026

From Innoviva, Inc.

Via Business Wire

3 Bargain-Cheap Small Caps Worth a Second Look ↗

April 09, 2026

Via MarketBeat

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential ↗

March 23, 2026

This clinical-stage biotech focuses on developing therapies for neurological and immunoscience disorders.

Via The Motley Fool

Topics Regulatory Compliance

Beyond The Numbers: 5 Analysts Discuss Innoviva Stock ↗

September 30, 2025

Via Benzinga

Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress

February 25, 2026

From Innoviva, Inc.

Via Business Wire

Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 19, 2026

From Innoviva, Inc.

Via Business Wire

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out ↗

January 08, 2026

Via MarketBeat

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

December 16, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

U.S. FDA Approves NUZOLVENCE® (zoliflodacin), a First-in-Class, Single-dose, Oral Antibiotic for the Treatment of Uncomplicated Urogenital Gonorrhea in Adults and Adolescents

December 12, 2025

From Innoviva, Inc.

Via Business Wire

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

December 11, 2025

From Innoviva, Inc.

Via Business Wire

Innoviva to Participate in the 37th Annual Piper Sandler Healthcare Conference

November 25, 2025

From Innoviva, Inc.

Via Business Wire

Stay updated with the stocks that are on the move in today's pre-market session. ↗

November 13, 2025

The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.

Via Chartmill

Value Investing Case Study: INNOVIVA INC (NASDAQ:INVA) ↗

November 11, 2025

Discover Innoviva (INVA), a potential value stock with strong fundamentals. Its attractive valuation, healthy balance sheet, and solid profitability suggest it trades below intrinsic worth.

Via Chartmill

Innoviva Reports Third Quarter 2025 Financial Results; Highlights Recent Company Progress

November 05, 2025

From Innoviva, Inc.

Via Business Wire

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

October 20, 2025

From Innoviva Specialty Therapeutics

Via Business Wire

Innoviva Specialty Therapeutics to Deliver Six Presentations from its Infectious Diseases and Critical Care Portfolio at IDWeek 2025

October 07, 2025

From Innoviva Specialty Therapeutics

Via Business Wire

Innoviva Inc (NASDAQ:INVA): A Prime Candidate for Value Investors Seeking Undervalued Stocks ↗

September 08, 2025

Discover Innoviva (INVA), a value stock with strong fundamentals. It trades below intrinsic value, boasts a healthy balance sheet, and has promising growth prospects in biopharma.

Via Chartmill

Innoviva to Participate in Upcoming Investor Conferences

August 26, 2025

From Innoviva, Inc.

Via Business Wire

Innoviva Inc (NASDAQ:INVA) Recognized as a "Decent Value" Stock with Strong Valuation and Growth Potential ↗

August 18, 2025

Innoviva (INVA) is a value stock with strong valuation metrics, solid financial health, and growth potential, making it an attractive pick for value investors.

Via Chartmill

Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award

August 13, 2025

From Innoviva Specialty Therapeutics, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.